PHARMACODYNAMIC AND PHARMACOKINETIC CHARACTERISTICS OF PHARMACOLOGICAL AGENTS USED IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: A COMPREHENSIVE SYSTEMATIC REVIEW

Authors

Keywords:

benign prostatic hyperplasia, pharmacodynamics, pharmacokinetics, alpha-1 adrenergic antagonists, 5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, uroselectivity

Abstract

Background: Benign prostatic hyperplasia (BPH) represents one of the most prevalent urological conditions affecting aging men worldwide, with an estimated prevalence exceeding 50% in men over 50 years of age and reaching up to 90% by the eighth decade of life. The pharmacological management of BPH has evolved substantially over the past three decades, encompassing multiple drug classes with distinct pharmacodynamic and pharmacokinetic profiles. Despite the widespread clinical use of these agents, a comprehensive comparative analysis of their pharmacological characteristics remains fragmented across the literature.

Objective: This systematic review aims to critically evaluate and compare the pharmacodynamic mechanisms of action, receptor selectivity profiles, absorption, distribution, metabolism, elimination, and drug–drug interaction potentials of the major pharmacological agents currently employed in BPH management, including alpha-1 adrenergic receptor antagonists, 5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, antimuscarinic agents, and beta-3 adrenergic agonists.

Methods: A systematic literature search was conducted across PubMed, Scopus, Web of Science, and the Cochrane Library databases for publications from January 2000 to December 2024. Inclusion criteria encompassed randomized controlled trials, pharmacokinetic studies, systematic reviews, and meta-analyses. Data extraction focused on pharmacodynamic parameters (receptor affinity, selectivity ratios, mechanism of action) and pharmacokinetic parameters (bioavailability, half-life, volume of distribution, protein binding, metabolic pathways, and clearance).

Results: Alpha-1 blockers demonstrated rapid onset of action (within hours to days) with varying degrees of uroselectivity (tamsulosin α1A/α1B ratio >20:1 vs. doxazosin non-selective). 5-alpha reductase inhibitors exhibited delayed therapeutic onset (3–6 months) with distinct isoform selectivity profiles (finasteride: type II selective; dutasteride: dual type I/II inhibition). Tadalafil demonstrated a unique dual-action mechanism with the longest half-life (17.5 hours) among PDE5 inhibitors. Significant inter-class variability was identified in hepatic metabolism pathways, with CYP3A4 and CYP2D6 playing predominant roles.

Conclusion: The pharmacological heterogeneity among BPH therapeutic agents necessitates individualized treatment selection based on patient-specific pharmacokinetic and pharmacodynamic considerations, comorbidity profiles, and concomitant medication regimens. Future research should prioritize pharmacogenomic investigations and head-to-head comparative pharmacokinetic studies.

References

1.Berry, S. J., Coffey, D. S., Walsh, P. C., & Ewing, L. L. (1984). The development of human benign prostatic hyperplasia with age. Journal of Urology, 132(3), 474–479.

2.Bramson, H. N., Hermann, D., Batchelor, K. W., Lee, F. W., James, M. K., & Frye, S. V. (1997). Unique preclinical characteristics of GG745, a potent dual inhibitor of 5α-reductase. Journal of Pharmacology and Experimental Therapeutics, 282(3), 1496–1502.

3.Chapple, C. R., & Roehrborn, C. G. (2006). A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on the bladder. European Urology, 49(4), 651–659.

4.Chung, M., Vashi, V., Edwin, M., Soldin, O., & Reeves, R. (2000). Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. British Journal of Clinical Pharmacology, 48(5), 678–687.

5.Daugan, A., Grondin, P., Ruault, C., Le Monnier de Gouville, A. C., Coste, H., Linget, J. M., ... & Kirilovsky, J. (2003). The discovery of tadalafil: A novel and highly selective PDE5 inhibitor. Journal of Medicinal Chemistry, 46(21), 4525–4532.

6.Djavan, B., & Marberger, M. (1999). A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. European Urology, 36(1), 1–13.

7.Fitzpatrick, J. M. (2006). Minimally invasive and medical therapies for benign prostatic hyperplasia. European Urology, 49(4), 620–626.

8.Forgue, S. T., Patterson, B. E., Bedding, A. W., Jewell, H., Payne, C. D., Wrishko, R. E., & Mitchell, M. I. (2006). Tadalafil pharmacokinetics in healthy subjects. British Journal of Clinical Pharmacology, 61(3), 280–288.

9.Gacci, M., Corona, G., Salvi, M., Vignozzi, L., McVary, K. T., Kaplan, S. A., ... & Maggi, M. (2017). A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology, 71(6), 994–1004.

10.Gravas, S., Cornu, J. N., Gacci, M., Gratzke, C., Herrmann, T. R., Karavitakis, M., ... & Kyriazis, I. (2021). EAU Guidelines on Management of Non-neurogenic Male LUTS. European Association of Urology Guidelines.

11.Hellriegel, E. T., Bjornsson, T. D., Hauck, W. W., & Robertson, P. (2011). Pharmacokinetics of tamsulosin in subjects with varying CYP2D6 metabolizer status. Journal of Clinical Pharmacology, 51(12), 1689–1697.

12.Kloner, R. A. (2007). Pharmacology and drug interaction effects of the phosphodiesterase type 5 inhibitors: Focus on α-blocker interactions. American Journal of Cardiology, 100(12), S42–S46.

13.Kupelian, V., Wei, J. T., O'Leary, M. P., Kusek, J. W., Litman, H. J., Link, C. L., & McKinlay, J. B. (2009). Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample. Archives of Internal Medicine, 166(21), 2381–2387.

14.Lepor, H. (2007). Alpha blockers for the treatment of benign prostatic hyperplasia. Reviews in Urology, 9(4), 181–190.

15.Lim, K. B. (2017). Epidemiology of clinical benign prostatic hyperplasia. Asian Journal of Urology, 4(3), 148–151.

16.Malik, M., van Gelderen, E. M., Lee, J. H., Kowalski, D. L., Yen, M., Goldwater, R., ... & Chen, W. (2012). Proarrhythmic safety of repeat doses of mirabegron in healthy subjects. Clinical Pharmacology & Therapeutics, 92(6), 696–706.

17.Markham, A. (2010). Silodosin: A review of its use in the treatment of signs and symptoms of benign prostatic hyperplasia. Drugs, 70(2), 191–201.

18.McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Dixon, C. M., Kusek, J. W., ... & Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. (2003). The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine, 349(25), 2387–2398.

19.Michel, M. C. (2008). The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: Bladder. Journal of Pharmacological Sciences, 106(2), 128–136.

20.Michel, M. C., & Vrydag, W. (2006). α1-, α2- and β-adrenoceptors in the urinary bladder, urethra and prostate. British Journal of Pharmacology, 147(S2), S88–S119.

21.Michelotti, G. A., Price, D. T., & Schwinn, D. A. (2001). Alpha 1-adrenergic receptor regulation: Basic science and clinical implications. Pharmacology & Therapeutics, 88(3), 281–309.

22.Narayan, P., & Tewari, A. (1998). Overview of α-blocker therapy for benign prostatic hyperplasia. Urology, 51(4), 38–45.

23.Nickel, J. C., Gilling, P., Tammela, T. L., Morrill, B., Wilson, T. H., & Rittmaster, R. S. (2011). Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: The Enlarged Prostate International Comparator Study (EPICS). BJU International, 108(3), 388–394.

24.Oelke, M., Bachmann, A., Descazeaud, A., Emberton, M., Gravas, S., Michel, M. C., ... & de la Rosette, J. (2013). EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European Urology, 64(1), 118–140.

25.Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., ... & Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71.

26.Porst, H., Oelke, M., Goldfischer, E. R., Cox, D., Oyarzabal, I., Garcia, J., ... & Watts, S. (2013). Efficacy and safety of tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results of a multinational, randomized, double-blind, placebo-controlled trial. Lower Urinary Tract Symptoms, 5(3), 117–126.

27.Roehrborn, C. G. (2008). Pathology of benign prostatic hyperplasia. International Journal of Impotence Research, 20(S3), S11–S18.

Published

2026-09-21